https://www.selleckchem.com/products/mln2480.html
Introduction Duvelisib, a first in class, oral, dual PI3 k-delta/gamma inhibitor recently received FDA approval for previously treated CLL (chronic lymphocytic leukemia)/SLL (small lymphocytic lymphoma) and follicular lymphoma. Data coming from the phase III 'DUO' trial, in fact, showed a superior progression-free survival (PFS) in CLL patients treated with duvelisib compared to ofatumumabAreas covered This review provides analysis of the mechanism of action of duvelisib and includes the rationale for the use of double inhibition. The a
Gefällt mir
Kommentar
Teilen
